Abstract
Transcriptional silencing of cancer‐related genes by DNA methylation is observed in various cancers. To identify genes controlled by methylation in prostate cancer, we used cDNA microarray analysis to investigate gene expression in prostate cancer cell lines LNCaP and DU145 treated with a methyltransferase inhibitor alone or together with a histone deacetylase inhibitor. We detected significant changes (3.4–5.7%) in gene expression in prostate cancer cell lines with the drug treatments. Among the affected genes, that for the vascular endothelial growth factor receptor 1 (VEGFR‐1) was re‐expressed in LNCaP and DU145 after the drug treatments. Bisulfite sequencing revealed the promoter and exon 1 of the VEGFR‐1 to be hypermethylated in the cell lines. These results support the idea that methylation is associated with loss of VEGFR‐1 mRNA expression in prostate cancer cell lines. Combined bisulfite restriction analysis (COBRA) showed the gene to be methylated in 24 (38.1%) of 63 primary local prostate cancer samples, while in all 13 benign prostate samples it was not. These findings indicate that methylation of VEGFR‐1 is related with prostatic carcinogenesis.
References
- 1. Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985; 45: 1437–43. [PubMed] [Google Scholar]
- 2. Ozen M, Pathak S. Genetic alterations in human prostate cancer: a review of current literature. Anticancer Res 2002; 20: 1905–12. [PubMed] [Google Scholar]
- 3. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21: 163–7. [DOI] [PubMed] [Google Scholar]
- 4. Bird AP, Wolffe AP. Methylation‐induced repression: belts, braces, and chromatin. Cell 1999; 99: 451–4. [DOI] [PubMed] [Google Scholar]
- 5. Nakayama T, Watanabe M, Yamanaka M, Hirokawa Y, Suzuki H, Ito H, Yatani R, Shiraishi T. The role of epigenetic modifications in retinoic acid receptor (32 gene expression in human prostate cancers. Lab Invest 2001; 81: 1049–57. [DOI] [PubMed] [Google Scholar]
- 6. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh W. S., Isaacs WB, Nelson WG. Cytidine methylation of regulatory sequences near the π‐class glutathione S‐transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994; 91: 11733–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB. E‐Cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinoma. Cancer Res 1995; 55: 5195–9. [PubMed] [Google Scholar]
- 8. Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, Vocke CD, Duh F, Zabarovsky E, Minna JD, Rhim JS, Emmert‐Buck MR, Linehan WM, Lerman MI. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 2002; 62: 3498–502. [PubMed] [Google Scholar]
- 9. Kawai J, Hirotsune S, Hirose K, Fushiki S, Watanabe S, Hayashizaki Y. Methylation profiles of genomic DNA of mouse developmental brain detected by restriction landmark genomic scanning (RLGS) method. Nucleic Acids Res 1993; 21: 5604–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe‐toyota M, Baylin SB, Issa JJ. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999; 59: 2307–12. [PubMed] [Google Scholar]
- 11. Ushijima T, Morimura K, Hosoya Y, Okonogi H, Tatematsu M, Sugimura T, Nagao M. Establishment of methylation‐sensitive‐representational difference analysis and isolation of hypo‐ and hypermethylated genomic fragments in mouse liver tumors. Proc Natl Acad Sci USA 1997; 94: 2284–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Huang TH, Perry MR, Laux DE. Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 1999; 8: 459–70. [DOI] [PubMed] [Google Scholar]
- 13. Vries CD, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms‐like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989–91. [DOI] [PubMed] [Google Scholar]
- 14. Kim JK, Li B, Winer J. Inhibition of vascular endothelial growth factor‐induced angiogenesis suppresses tumor growth in vivo . Nature 1993; 362: 841–4. [DOI] [PubMed] [Google Scholar]
- 15. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molly PL, Pail CL. A genomic sequencing protocol that yields a positive display of 5‐methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992; 89: 1827–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997; 25: 2532–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowits S, Willson JK, Hamilton SR, Kinzler KW, Kane M, Kolodner R, Vogelstein B, Kunkel T, Baylin S. Incidence and functional consequences of hMLHl promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95: 6870–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Roman‐Gomez J, Castillejio JU, Jimenez A, Gonzalez MG, Moreno F, Rodriguez MC, Barrios M, Maldonado J, Torres A. 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21crp1/WAF1/SDI1 gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 2002; 99: 2291–6. [DOI] [PubMed] [Google Scholar]
- 19. Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5‐Aza‐2′‐deoxycytidine. Cancer Res 2002; 62: 961–6. [PubMed] [Google Scholar]
- 20. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002; 21: 5496–503. [DOI] [PubMed] [Google Scholar]
- 21. Morishita K, Johnson DE, Williams LT. A novel promoter for vascular endothelial growth factor receptor (flt‐1) that confers endothelial‐specific gene expression. J Biol Chem 1995; 270: 27948–53. [DOI] [PubMed] [Google Scholar]
- 22. Terman BI, Dougher‐Verman M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579–86. [DOI] [PubMed] [Google Scholar]
- 23. Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing antivascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre‐clinical model. J Urol 1999; 161: 960–3. [PubMed] [Google Scholar]
- 24. Kearney JB, Amber CA, Monaco KA, Johnson N, Rapoport RG, Bautch VL. Vascular endothelial growth factor receptor Flt‐1 negatively regulates developmental blood vessel formation by modulating endothelial cell division. Blood 2002; 99: 2397–407. [DOI] [PubMed] [Google Scholar]
- 25. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999; 54: 567–72. [DOI] [PubMed] [Google Scholar]
- 26. Hahn D, Simak R, Ateiner GE, Handisurya A, Susani M, Marberger M. Expression of the VEGF‐receptor Flt‐1 in benign, premalignant and malignant prostate tissues. J Urol 2000; 164: 506–10. [PubMed] [Google Scholar]
- 27. Huss WJ, Hanrahan CF, Barrios RJ, Siomns JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001; 61: 2736–43. [PubMed] [Google Scholar]
- 28. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Horsfall DJ, Tilley WD. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002; 62: 854–9. [PubMed] [Google Scholar]